Clinical Trial Update: Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating safety, efficacy and treatment satisfaction in patients with pulmonary arterial hypertension rapidly switched from epoprostenol …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Epoprostenol (Epoprostenol)
• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2013-01-07